Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elusys Therapeutics has received $68.9m funding from the US Government to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.
Subscribe to our email newsletter
The funding will be used in multiple animal efficacy studies as well as human safety studies to further demonstrate the utility of Anthim (ETI-204), to prevent disease and death from exposure to anthrax when administered intramuscularly before symptoms of disease are present.
Anthim is an anti-toxin that significantly increases survival in anthrax-infected animals and is a promising candidate for the treatment of anthrax infection in people following a biowarfare attack.
Elusys president and CEO Elizabeth Posillico said in several animal studies conducted to date, ETI-204 has demonstrated excellent efficacy and increased survival significantly when given in a single intramuscular dose.
Elusys Research vice president Leslie Casey said in a recent animal study, a single IM dose of Anthim provided a 92% survival rate when administered 18 hours after exposure to anthrax.